On Thursday, the FDA approved Bristol Myers Squibb & Co's (NYSE:BMY) Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults.
Bristol-Myers added the treatment via Karuna Therapeutics deal for $330 per share in cash for a total equity value of $14 billion.
Cobenfy represents the first new class of medicine in several decades and introduces a fundamentally new approach to treating schizophrenia by selectively targeting M1 and M4 receptors in the brain without blocking D2 receptors.
"Today's landmark approval of our first-in-class treatment for schizophrenia marks an important milestone for the community, where after more than 30 years, there is now an entirely new pharmacological approach for schizophrenia — one that has the potential to change the treatment paradigm," said Chris Boerner, board chair and CEO at Bristol Myers Squibb.
Schizophrenia is estimated to impact approximately 2.8 million people in the U.S.
The FDA approval of Cobenfy is supported by data from the EMERGENT clinical program, which includes three placebo-controlled efficacy and safety trials and two open-label trials evaluating the long-term safety and tolerability of COBENFY for up to one year.
In Phase 3 EMERGENT-2 and EMERGENT-3 trials, Cobenfy met its primary endpoint, demonstrating statistically significant reductions of schizophrenia symptoms compared to placebo, as measured by the Positive and Negative Syndrome Scale (PANSS) total score change from baseline to week five.
Cobenfy demonstrated a 9.6-point reduction (-21.2 Cobenfy vs. -11.6 placebo) and an 8.4-point reduction (-20.6 Cobenfy vs. -12.2 placebo) in PANSS total score compared to placebo at week five in EMERGENT-2 and EMERGENT-3, respectively.
In EMERGENT-2, Cobenfy demonstrated a statistically significant improvement in illness from baseline to week five.
Cobenfy was invented at PureTech Health Plc (NASDAQ:PRTC). FDA approval triggers two separate milestone payments to PureTech totaling $29 million.
美國食品藥品管理局週四批准了百時美施貴寶公司(紐約證券交易所代碼:BMY)的Cobenfy(xanomeline and trospium chloride,karXT),這是一種治療成人精神分裂症的口服藥物。
百時美通過 Karuna Therapeutics 公司以每股 330 美元的現金收購了該療法,總股本價值達 140 億美元。
Cobenfy是幾十年來的第一類新藥物,它通過選擇性地靶向大腦中的M1和M4受體而不阻斷D2受體,引入了一種治療精神分裂症的全新方法。
Bristol Myers Squibb董事會主席兼首席執行官克里斯·博爾納表示:「今天我們的首創精神分裂症療法獲批具有里程碑意義,這對於社區來說是一個重要的里程碑,30多年後,現在有了一種治療精神分裂症的全新藥理方法——這種方法有可能改變治療模式。」
據估計,精神分裂症將影響美國約280萬人。
美國食品藥品管理局對Cobenfy的批准得到了Emergent臨床項目數據的支持,該項目包括三項安慰劑對照的療效和安全性試驗,以及兩項評估COBENFY長達一年的長期安全性和耐受性的開放標籤試驗。
在3期Emergent-2和Emergent-3試驗中,Cobenfy達到了其主要終點,根據從基線到第五週的陽性和陰性綜合徵量表(PANSS)總分變化來衡量,與安慰劑相比,精神分裂症的症狀明顯減輕。
在Emergent-2和Emergent-3的第五週中,與安慰劑相比,Cobenfy的PANSS總分分別下降了9.6個百分點(-21.2 Cobenfy對比-11.6個安慰劑)和8.4個百分點(-20.6個Cobenfy對比-12.2安慰劑)。
在Emergent-2中,Cobenfy顯示,從基線到第五週,病情有了統計學上的顯著改善。
Cobenfy 由 PureTech Health Plc(納斯達克股票代碼:PRTC)發明。FDA批准後,PureTech 將分別獲得兩筆里程碑付款,總計 2900 萬美元。